Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Asset Writedowns and Impairment (2020 - 2025)

Bioventus' Asset Writedowns and Impairment history spans 6 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 601.68% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 96.21%, while the annual FY2025 figure was $1.3 million, 389.4% up from the prior year.
  • Asset Writedowns and Impairment reached $1.3 million in Q4 2025 per BVS's latest filing, up from -$650000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $79.3 million in Q4 2023 to a low of -$976000.0 in Q1 2024.
  • Average Asset Writedowns and Impairment over 5 years is $8.0 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Asset Writedowns and Impairment: skyrocketed 759.41% in 2021, then tumbled 190.45% in 2024.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $7.2 million in 2021, then surged by 43.23% to $10.3 million in 2022, then skyrocketed by 671.12% to $79.3 million in 2023, then tumbled by 99.77% to $179000.0 in 2024, then skyrocketed by 601.68% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Asset Writedowns and Impairment are $1.3 million (Q4 2025), -$650000.0 (Q2 2025), and $650000.0 (Q1 2025).